MOUNTAINSIDE, N.J., March 16, 2016 /PRNewswire/ -- Androvia LifeSciences, a biotechnology company engineering solutions for the advancement of male fertility, today announced that data related to the company's proprietary technology, the Cap-Score™ Sperm Function Test, will be presented in an oral session at the 41st Annual Conference of the American Society of Andrology (ASA), to be held April 2 – 5, 2016 in New Orleans, Louisiana. Three additional studies related to the Cap-Score Sperm Function Test will be presented in poster sessions.
"The Cap-Score Sperm Function Test fills a gap in measuring male fertility. Knowledge of whether a man's sperm can actually fertilize an egg can complement the traditional semen analysis. This will allow clinicians and couples to choose the optimal solution for men with infertility and couples having difficulty conceiving," said Michael V. Novinski, chief executive officer, Androvia LifeSciences.
The four studies being presented at the ASA annual conference this year are:
Consistent differences among men in capacitation timing could personalize IUI/ART
Normal ejaculates, as defined by WHO, can have abnormal capacitation ability
Sperm from fertile men and those seeking fertility exams differ in their ability to capacitate
Reliability estimates for a test of sperm capacitation, a functional complement to semen analysis
Abstracts summarizing these data were published today on the ASA website and are available to conference registrants and ASA members at: http://andrologysociety.org/meetings/asa-annual-meeting/future-meetings/2016-asa-abstract-sessions.aspx.
About Cap-Score Sperm Function Test
A laboratory developed test being designed to assess and measure the fertilizing ability of sperm, to help couples and reproductive health care professionals make informed decisions about the fertility solution that is best suited for that couple. The Cap-Score Sperm Function Test provides an analysis of the sperm on a molecular level, and is the only assay that evaluates capacitation, the process by which sperm acquire the ability to fertilize an egg. The test is being designed to complement the traditional semen analysis which determines sperm count, motility and appearance.
About Androvia LifeSciences
Androvia LifeSciences is a biotechnology company focused on engineering scientific technology for the advancement of male fertility, and empowering couples with the information to help determine personalized fertility solutions.
SOURCE Androvia LifeSciences